Thyronamines: novel bioactive metabolites of thyroid hormone
OHSU # 0674
NOVEL BIOACTIVE METABOLITES OF THYROID HORMONE:
A SAFE AND EFFECTIVE TREATMENT FOR DISEASE
OHSU Technology 0674
Researchers at Oregon Health & Science University and University of California, San Francisco discovered and validated a new class of thyroid hormone metabolites. The most potent of these, 3-iodothyronamine, has been shown in animal studies to completely switch fuel utilization away from carbohydrates and toward lipids. Compounds in this class include both selective agonists and antagonists of the G-protein coupled receptor, TAAR-1. Ex vivo studies demonstrate that the compounds significantly increase cardiac output and decrease systemic vascular resistance with no change in heart rate or blood pressure, therefore demonstrating proof of concept for treatment of congestive heart failure. Further, a broad spectrum of in vivo studies with the thyronamines positively supports their use for treating thyroid hormone disorders, hyper- and hypoglycemia, obesity, and depression and mood disorders.
Thomas S. Scanlan, PhD, is the Program Director in Chemical Biology and Professor of Physiology and Pharmacology. Dr. Scanlan’s research focuses on developing and understanding the molecular basis of thyroid hormones in a multidisciplinary approach that involves synthetic chemistry, biochemistry, cell biology, and ultimately physiology.
David Grandy, PhD, is Professor of Physiology and Pharmacology. Dr. Grandy’s research focuses on complex signaling systems, particularly G protein-coupled receptor proteins with a combination of molecular, cellular, and behavioral approaches to explore opiate tolerance and drug dependence.
Issued patent 7,321,065
OHSU Technology 0674 is available for exclusive licensing.
Scanlan T, Suchland K, Hart M, Chiellini G, Huang Y, Kruzich P, Frascarelli S, Crossley D, Bunzow J, Ronca-Testoni S, Lin E, Hatton D, Zucchi R, Grandy D, 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone, Nat. Med. 10 (6): 638–42 (2004).
- David Grandy, SM.Physiology & Pharmacology
- James Bunzow, VI.Vollum Institute
- Thomas Scanlan, SM.Phys and Pharm
- Matthew Hart
- Katherine Suchland
|Issued||United States||7,321,065 B2|
For more information, contact:
Senior Technology Development Manager